After publication of the favourable cardiovascular (CV) results with empagliflozin in the EMPA-REG OUTCOME Study [1, 2] and with liraglutide in the LEADER Study [3, 4] , several diabetologists announced the begin of a "new era" for therapy of type 2 diabetes: Metformin should remain the first drug, but then, for escalation of therapy, one of these two drugs should be added instead of other antidiabetics. There was even the proposal to start pharmacotherapy of type 2 diabetes with a combination of liraglutide and empagliflozin, irrespective of the high price, especially since they exert their beneficial CV actions on different points of pathogenetic pathways which are, however, not fully understood.
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Such claims seem to be not yet justified and inclusion into guidelines is unwarranted at present. The results of the two studies were obtained in patients with diabetes and CV events or at a very high CV risk and thus cannot be automatically extrapolated for all type-2 diabetes patients. They were designed as CV safety trials. According to a scientific principle they have to be confirmed in at least one or two other studies. The EMPA-REG and LEADER CV results should not be compared with the benefits seen with statins as this has been shown in about 30 other studies [5] . With Lixisenatide, another GLP-1 agonist, no cardiovascular benefit was found [6] . At the 52th Congress of the European Association for the Study of Diabetes (EASD) in Munich on September 16 th , 2016, however, positive CV results of the SUSTAIN 6 study have been presented for semaglutide, also a glucagon-like peptide-1 analogon [7] [8] [9] . On the other hand, a significant deterioration of diabetic retinopathy was observed with semaglutide; a similar tendency was found also with liraglutide in the LEADER study. Open Access
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FDA regulations since 2008. Heart failure also has to be included now. Therefore, the pharmaceutic companies perform "non-inferiority" studies, and, concomitantly, try to find "superiority" with much financial support by increasing the number of patients to reach necessary statistical power. Many studies find a "non-inferiority" and also "no superiority" for their drug, e.g. for sitagliptin in the TECOS study [10] . Some diabetologists have already questioned the sense of the FDA´s requirement in its present form for expensive non-inferiority studies, and also their extension by the pharmaceutic companies for finding "superiority" which make them still more costly.
After many neutral or even negative CV outcome studies with hypoglycaemic agents , the beneficial CV results with empagliflozin and liraglutide, and now also semaglutide, are highly welcome and give hope for further prolongation of life span and improvement of quality of life for patients with type 2 diabetes (Table 1) . However, long-term effects on outcome including side effects have yet to be evaluated. Of special interest will be the findings in the ongoing CAROLINA study which compares the outcomes with the DPP4-inhibitor linagliptin and sulphonylureas. This study will be finished in September 2018 and will substantially contribute to the still ongoing discussion whether sulphonylureas are outdated or not [10] .
Treatment of type 2 diabetes is becoming more complicated and personalized. Every patient should be treated not only based on study results but also on the individual characteristics e.g. age, body weight, age at manifestation, disease duration, blood pressure, CV events and renal status, and also the patient's preferences, e.g. for oral or injectable therapy.
Finally, it should be stressed that with every new drug the advantages can be mostly seen quite early. The long-term efficacy and safety including unwarranted adverse events can be judged only later, after years or even decades. They are, however, well documented for the old antidiabetics e.g. insulin and sulphonylureas. Their positive and negative effects -weight gain and hypoglycemia -are well known and they should be to handle by experienced physicians together with their educated patients.
Insulin remains "das kleine Schwarze" (the little black dress, suitable for all occasions) as it has been called in German commentaries. Insulin fits as combination partner to every antidiabetic drug. The author would call insulin rather the "big evening dress", after the ORIGIN and other studies, compared to all other oral and injectable forms of therapy. It has the strongest antihyperglycemic potential of all. One has to wait and see, if, or to which extent the various extrahypoglycemic beneficial CV actions of the new drugs compensate, or hopefully overcome the weaker glucoselowering effects over longer time periods. They should also become cheaper.
At the moment, the present algorithms for treatment of type-2 diabetes should not yet be changed.
